Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved TherapiesGlobeNewsWire • 09/24/25
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted TherapyGlobeNewsWire • 09/17/25
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous MalformationsGlobeNewsWire • 09/15/25
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.GlobeNewsWire • 09/03/25
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/25
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025GlobeNewsWire • 08/07/25
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 08/05/25
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%GlobeNewsWire • 06/23/25
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR InhibitorsGlobeNewsWire • 06/18/25
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsGlobeNewsWire • 06/09/25
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial OfficerGlobeNewsWire • 05/27/25
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/25
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025GlobeNewsWire • 05/08/25
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative DermatologyGlobeNewsWire • 04/23/25
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic MalformationsGlobeNewsWire • 04/22/25
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric DermatologyGlobeNewsWire • 04/11/25
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric DermatologyGlobeNewsWire • 04/02/25
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/31/25
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025GlobeNewsWire • 03/18/25
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare ConferenceGlobeNewsWire • 02/25/25